These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 36319109)

  • 1. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1.
    Costamagna G; Govoni A; Wise A; Corti S
    Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
    Aslesh T; Yokota T
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
    Li Y; Zeng H; Wei Y; Ma X; He Z
    Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of Spinal Muscular Atrophy].
    Ishiyama A
    Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in spinal muscular atrophy research.
    Wurster C; Petri S
    Curr Opin Neurol; 2022 Oct; 35(5):693-698. PubMed ID: 35942665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
    McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
    Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
    Blair HA
    CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging targeted therapies for spinal muscular atrophy.
    Lakhina Y; Boulis NM; Donsante A
    Expert Rev Neurother; 2023; 23(12):1189-1199. PubMed ID: 37843301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
    Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ
    Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life.
    Steffens P; Weiss D; Perez A; Appel M; Weber P; Weiss C; Stoltenburg C; Ehinger U; von der Hagen M; Schallner J; Claussen B; Lode I; Hahn A; Schuler R; Ruß L; Ziegler A; Denecke J; Johannsen J
    Eur J Paediatr Neurol; 2024 Jul; 51():17-23. PubMed ID: 38772209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
    Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
    Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.
    Chiriboga CA
    Paediatr Drugs; 2022 Nov; 24(6):585-602. PubMed ID: 36028610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
    Abreu NJ; Waldrop MA
    Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.